Qualigen launches Rosuvastatin to treat high cholesterol and to prevent cardiovascular disease

26/04/2018

Qualigen launches Rosuvastatina 5 mg, 10 mg and 20 mg film-coated tablets EFG.

Rosuvastatina Qualigen EFG is bioequivalent to Crestor® and is indicated to treat high cholesterol and to prevent cardiovascular disease. 

Rosuvastatine Qualigen is marketed in presentations of 28 tablets of 5 mg, 10 mg and 20 mg.

Rosuvastatine Qualigen requires a prescription for dispensing and is financed by the Spanish Health System with reduced contribution.

With this launch, Qualigen extends its product portfolio of drugs to prevent cardiovascular disease.


Source:
http://www.invent-farma.es/qualigen-launches-rosuvastatin-n-66-en.html

Share:

This website uses cookies, both own and third parties to collect statistical information about navigation and show advertising related to your preferences, generated from their navigation patterns. If you continue to browse, consider accepting its use. You can change the settings or get more information on cookies here.